1-877-804-4900

facetime_banner

Clinical Home Page Slider 2014

Clinical oversight for injured workers to prevent abuse

bannernew

websitebanner1

Ancillary Benefits Management for Workers’ Compensation

websitebanner2

Mobile app for workers compensation

About Us

myMatrixx provides pharmacy and ancillary services for workers’ compensation programs. Our services control costs with proactive clinical oversight throughout the claims process. With one online tool also available in a mobile app, clients can manage claims with real time data and detailed reporting.

Learn more

The Latest

News

myMatrixx Chief Clinical Officer Phil Walls Honored as CompPharma’s 2015 Person of the Year

Posted by On December 22, 2015

TAMPA, FL, December 18, 2015 – Phil Walls, Chief Clinical Officer for myMatrixx, has been recognized as CompPharma’s Person of the Year for 2015. CompPharma is a consortium of workers’ compensation pharmacy benefit management (PBM) companies that provides a platform for developing cost-effective tools and services that benefit its PBM members.  myMatrixx, a Tampa-based pharmacy […]

myMatrixx President Artemis Emslie Named to 2015 “Women to Watch” List

Posted by On December 21, 2015

One of 25 Women Honored as Leaders in the Insurance Industry TAMPA, December 8, 2015 – myMatrixx, a Tampa-based pharmacy and ancillary medical benefit management company, announced that Artemis Emslie, President of myMatrixx, has been recognized by Business Insurance magazine as an honoree on their 2015 “Women to Watch” list. The annual list spotlights 25 […]

Blog

New “N” Drug Classifications in Texas and Oklahoma: Essential Information for Claims Professionals

Posted by On November 09, 2015

by Phil Walls, myMatrixx Chief Clinical Officer The Texas Department of Insurance Division of Workers’ Compensation has announced that both Duragesic® (fentanyl) transdermal system patches and MS Contin® (morphine sulfate) extended-release tablets will be classified as “N” Drugs, effective February 1, 2016.  These drugs belong to a drug class known as long-acting opioids, which also […]

Drug of the Month: Relistor® A Step-Therapy Approach to Opioid-Induced Constipation

Posted by On November 02, 2015

By: Rachel Crowe, PharmD Candidate 2016 Alan Rook, PharmD 1. What is Relistor®? Relistor® (methylnaltrexone bromide), manufactured by Valeant Pharmaceuticals International, Inc., is FDA approved for opioid-induced constipation in patients with chronic non-cancer pain as well as opioid-induced constipation with advanced illness. Opioid analgesics are able to cross the blood brain barrier (BBB) and act […]

Visit Blog

Videos

View All